News & Updates

A recent study in the Philippines has identified key demographic and behavioural patterns among Filipino men who have sex with men (MSM) and transgender individuals (TGIs) regarding their awareness of pre-exposure prophylaxis (PrEP) and modality preferences.

A recent study suggests that the use of hormone therapy does not contribute to increased women with severe symptoms of COVID-19.

Held in June 2025 in Singapore, the Pfizer COVID-CONNECT Masterclass convened international experts to discuss the evolving challenges of COVID-19. Co-chaired by Dr Asok Kurup and Dr Luke Moore, this event assessed the ongoing global impact of the disease and explored evidence-based strategies across the patient journey from early identification to effective treatment.

The use of oseltamivir for treating influenza episodes in children appears to lower the risk of serious neuropsychiatric events, according to a retrospective cohort study.

At the recent COVID-CONNECT Masterclass, an expert-led session explored where COVID-19 stands among common viral infections today. In a non-promotional symposium supported by Pfizer, infectious disease specialist Dr Leong Hoe Nam, Mount Elizabeth Hospital Novena, Singapore, discussed strategies for managing viral infections and surge preparedness. Complementing this, Professor David Strain from the University of Exeter Medical School, UK highlighted the enduring burden of long COVID.

The IMPROVE trial shows the feasibility and safety of 1-month isoniazid and rifapentine (1HP) in an inpatient setting as tuberculosis preventive therapy (TPT) in patients with advanced HIV disease (AHD) and cryptococcal meningitis (CM).

Treatment with emtricitabine/tenofovir alafenamide (F/TAF) and cobicistat-boosted atazanavir (ATV/c) or darunavir (DRV/c) maintained high rates of virologic suppression through 48 weeks in children living with HIV, based on two cohorts from the GS-US-216-0128 study presented at IAS 2025.

Switching to maintenance dual antiretroviral therapy (ART) with DTG+3TC* or ATV/r+3TC** was noninferior to continuing triple current ART with TDF+3TC+EFV*** or DTG+3TC+TDF⁺ in maintaining virologic suppression for up to 96 weeks among people living with HIV (PLWH), according to the MODERATO trial presented at IAS 2025.